UK study shows mixing Pfizer and AstraZeneca COVID-19 vaccines with Moderna elicits better immune response
Results show support in favour of heterologous dosing which may help to advance vaccination programmes in poorer countries.
We use necessary cookies to make our site work. We'd also like to set analytical cookies to help us improve our service, but we'd like your permission first. Please choose which cookies you're happy for us to set.